Released Aug 13, 2021, after the close
10-Q filed Aug 13, 2021, 44 days after period end · 0001140361-21-028301
Q2 2021 · 10-Q
Revenue—
Net Income-$10.09M-$10.09M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.24-$0.24 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$10,013,000N/M
Operating Cash Flowderived-$6,804,000N/M
Free Cash Flowderived-$6,804,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | — | $754.00K | $5.23M | $5.65M |
| Net Income | -$10.09M | -$2.03M | -$90.00K | -$124.00K |
| EPS Diluted | -$0.24 | -$0.12 | -$0.03 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR